<DOC>
	<DOCNO>NCT01392911</DOCNO>
	<brief_summary>This first trial series clinical trial aim bring concept high dose rifampicin beyond phase II clinical development . The safety , tolerability , extend early bactericidal activity ( EBA ) pharmacokinetics several dos Rifampicin without standard dos Isoniazid , Pyrazinamide Ethambutol adult newly diagnose , uncomplicated , smear positive , pulmonary TB assess . The objective study find maximum tolerable dose Rifampicin monotherapy combination currently available Isoniazid , Pyrazinamide Ethambutol . The subject study 24-31 day . After screen period 9-3 day , subject receive treatment Rifampicin single drug 7 day ( monotherapy ) . This treatment follow treatment 7 day Rifampicin Isoniazid , Pyrazinamide Ethambutol ( combination therapy ) , 7-8 day treatment standard TB medication . All subject closely monitored side effect . This monitoring include daily interview physical examination , ECG evaluation blood urine analyse specific interval . During 7 day monotherapy , second day combination therapy end combination therapy , overnight sputum collect patient investigate potency high dose rifampicin reduce number bacillus . The Rifampicin dose increase step step group group . The control group receive standard dose 10 mg Rifampicin/kg , whereas first treatment group receive 20 mg/kg . The Rifampicin dose increase next group patient , expect safe . Rifampicin widely available expensive . Physicians world experience drug adverse effect . Should study successful , high dose Rifampicin safe tolerable give large group patient . next study . If increase dose Rifampicin prove safe effective , high dose Rifampicin could implement broadly quickly , would benefit many patient worldwide .</brief_summary>
	<brief_title>Safety , Tolerability , Extended Early Bactericidal Activity PK Higher Doses Rifampicin Adults With Pulmonary TB</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>1 . The patient able willing provide write , informed consent prior trialrelated procedure include HIV testing . 2 . The patient age 18 65 year , inclusive . 3 . The patient body weight ( light clothing shoe ) 40 85 kg , inclusive . 4 . The patient newly diagnose , previously untreated , uncomplicated , sputum smearpositive , pulmonary TB patient . 5 . The patient normal chest Xray picture opinion Investigator compatible TB . 6 . The patient sputum positive direct microscopy acidfast bacillus ( least 1+ IUATLD/WHO scale ( Appendix 4 ) ) . 7 . The patient able produce adequate volume sputum estimate spot assessment ( estimate 10 ml overnight production ) . 8 . The patient negative serum pregnancy test ( female subject childbearing potential ) 9 . The patient agree use highly effective method birth control ( i.e . two follow precaution : tubal ligation , vaginal diaphragm , intrauterine device , condom , oral contraceptive , contraceptive implant , combine hormonal patch , combine injectable contraceptive depotmedroxyprogesterone acetate , partner ( ) has/have vasectomy ) throughout participation trial 1 week last dose , unless partner ( ) sterile ( , woman bilateral oophorectomy and/or hysterectomy postmenopausal least 12 consecutive month ; men bilateral orchidectomy ) . 10 . A Karnofsky score least 60 ( require occasional assistance able care his/her need ) . 1 . The patient poor general condition delay treatment tolerate per discretion Investigator . 2 . Rifampicinresistant bacteria detect patient 's sputum specimen collect within PreTreatment Period test study laboratory . 3 . The patient receive treatment drug active MTB within 3 month prior Visit 1 : isoniazid , ethambutol , amikacin , cycloserine , rifabutin , rifampicin , streptomycin , kanamycin , paraaminosalicylic acid , rifapentine , pyrazinamide , thioacetazone , capreomycin , quinolones , thioamides . 4 . The patient history allergy isoniazid , ethambutol , rifampicin pyrazinamide , 5 . The patient history previous TB . 6 . The patient Hepatitis B . 7 . The patient Hepatitis C. 8 . The patient infect HIV CD4 count &lt; 350 cells/uL ( Visit 1 ) . 9 . The patient receive antiretroviral therapy ( ART ) . 10 . The patient take rifampicin within 30 day prior Visit 1 . 11 . The patient diabetic use insulin . 12 . The patient pregnant breastfeeding ( female patient ) . 13 . The patient history and/or presence ( evidence ) neuropathy epilepsy . 14 . The patient history current clinically relevant cardiovascular disorder : 1. heart failure , coronary heart disease , hypertension , arrhythmia , tachyarrhythmia status myocardial infarction . 2. family history sudden death unknown cardiacrelated cause , prolong QTc interval . 15 . Concomitant use drug know prolong QTc interval ( include amiodarone , bepridil chloroquine , chlorpromazine , cisapride , clarithromycin , disopyramide dofetilide , domperidone , droperidol , erythromycin , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozide , procainamide , quinidine , sotalol , sparfloxacin , thioridazine ) . 16 . The patient disease condition use standard TB drug component contraindicate , include limited allergy TB drug component . 17 . There clinically significant evidence extrathoracic TB ( miliary TB , abdominal TB , urogenital TB , osteoarthritic TB , TB meningitis ) , judge Investigator . 18 . Evidence serious lung condition TB uncontrolled obstructive bronchial disease . 19 . The patient clinically relevant change ECG atrioventricular ( AV ) block , prolongation QRS complex 120 millisecond , either QTcF QTcB interval 450 millisecond screen ECG . 20 . There evidence show patient renal impairment , include limited serum creatinine level upper limit laboratory reference range . 21 . The patient abnormal alanine aminotransferase ( ALT ) and/or aspertate transferase ( AST ) level &gt; 1 time upper limit laboratory reference range ( Visit 1 ) . 22 . There evidence show patient clinically significant metabolic , gastrointestinal , neurological , psychiatric endocrine disease , malignancy , abnormality ( indication study ) . 23 . The patient disease condition medicinal product list section pertain prohibit medication use . 24 . The patient know suspect , current history drug amphetamine abuse , within past 2 year , , opinion Investigator , sufficient compromise safety cooperation patient . 25 . The patient know suspected current history significant alcohol consumption , i.e . 20 units/week , within past 2 year . 26 . The patient use drug substance know strong inhibitor inducer cytochrome P450 enzyme within 30 day prior Visit 4 ( include xenobiotics , quinidine , tyramine , ketoconazole , testosterone , quinine , gestodene , metyrapone , phenelzine , doxorubicin , troleandomycin , cyclobenzaprine , erythromycin , cocaine , furafylline , cimetidine , dextromethorphan ) . Exceptions may make patient received 3 day less one drug substance , washout period prior Visit 4 equivalent least 5 halflives drug substance . 27 . The patient use therapeutic agent know alter major organ function ( e.g. , barbiturate , phenothiazine , cimetidine ) within 14 day prior Visit 4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Dose Ranging</keyword>
	<keyword>Extended Early Bactericidal Activity</keyword>
	<keyword>Maximum tolerable dose</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pulmonary Tuberculosis</keyword>
	<keyword>Rifampicin</keyword>
	<keyword>Rifafour</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Max Tolerable Dose</keyword>
</DOC>